

DCS/AMAL-Part B/ND/ 107 /2016-17
December 21, 2016

The Company Secretary
GRANULES INDIA LTD
2nd Floor, Block III, My Home Hub,
Madhapur ,Hyderabad – 500081
Telangana.

Dear Sir,

Sub: Scheme of Amalgamation of GIL Lifesciences Pvt. Limited with Granules India Limited

We refer to the Order of Hon'ble High Court of Hyderabad pertaining to Scheme of Amalgamation filed by the Company in compliance with Part II (A)(2), Annexure I of SEBI Circular No. CIR/CFD/CMD/16/2015 dated November 30, 2015.

SEBI vide its letter dated December 15, 2016 has given its comments on the approved Scheme of Amalgamation as per Annexure I (copy attached).

The comments communicated in the above SEBI letter refer to inter alia:

- a) "Documents submitted by the company have been noted."
b) " Stock Exchanges is advised to ensure compliance with the said circulars."
c) "Please note that the submission of documents/information in accordance with the circular, to SEBI should not in any way be deemed or construed that the same has been cleared or approved by SEBI. SEBI does not take any responsibility either for the financial soundness of any scheme or for the correctness of the statements made or opinions expressed in the documents submitted."

You are requested to take note of the same.

Yours faithfully,


Nitin Pujari
Manager

MD
Encl: as above.



Assistant Manager
Corporation Finance Department
Division of Issues and Listing
Phone: +91 22 26449262 / +91 22 40459262
Fax: +91 22 26449031 || Email: abhishekd@sebi.gov.in

भारतीय प्रातभूत
और विनिमय बोर्ड
Securities and Exchange
Board of India

CFD/DIL/BNS/AKD/ 33812, 12016

December 15, 2016

Shri Khushro Bulsara
Senior General Manager,
Bombay Stock Exchange Ltd.
Floor 25, P J Towers, Dalal Street,
Mumbai - 400 001.

BSE LTD. Received on	
Date:	20 DEC 2016
RCD	

Mr. Bulsara
Rep 27/12/16
2016-13744

Sir,

Sub: Comments on Scheme of Amalgamation of GIL Lifesciences Private Limited with Granules India Limited.

1. This has reference to your letter LIST/LO/SEBI/MR/103/2016-17 dated November 17, 2016 whereby you have forwarded the documents pertaining to Scheme of Amalgamation of GIL Lifesciences Private Limited with Granules India Limited filed in compliance with Part II, Annexure I of SEBI Circular No. CIR/CFD/CMD/16/2015 dated November 30, 2015.
2. Documents submitted in this regard have been noted.
3. Stock exchanges are advised to ensure compliance with the said Circulars.
4. Please note that the submission of documents/information in accordance with the Circular, to SEBI should not in any way be deemed or construed that the same has been cleared or approved by SEBI. SEBI does not take any responsibility either for the financial soundness of any scheme or for the correctness of the statements made or opinions expressed in the documents submitted.

Yours faithfully,


Abhishek Kumar D

Shri Janardhan Gujran
Chief Manager,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051.